Revolutionizing Topical Drug delivery to Create Targeted Therapeutic Solutions for Diseases of the Skin and Nails
Nitric Bio is a venture-backed biopharmaceutical and medical device company initially focused on developing and commercializing proprietary pharmacologic therapies that address attractive opportunities in the dermatology and podiatry markets. Our development activities focus on diseases where there is a medical need for greater localized delivery of a therapeutic action that is not being fulfilled by available systemic and topical drugs.
Our lead technology platform uses iontophoresis, which is the use of
electric current to optimize penetration of patented, uniquely formulated
drug through skin and nails. Iontophoresis delivers therapeutic levels of
proven
drugs directly into the skin and nails, thereby avoiding systemic side effects.
Click the link to learn
more about our
iontophoresis platform.
Our second technology platform utilizes nitric oxide gas, a potent antimicrobial and anti-inflammatory molecule, delivered topically for the treatment and prevention of skin infections, including those from drug-resistant bacteria such as MRSA. Click the link to learn more about our nitric oxide platform.
We have advanced product candidates from each platform into human clinical trials.
Nitric BioTherapeutics Initiates Phase II Onychomycosis Study
Appoints Al Altomari as Executive Chairman of the Board and Announces Closing of Financing Round
TECHNOLOGY PLATFORMS
Click on the links below to learn more about our technology platforms, their uses and application.